Amgen expects approval for Xgeva as bone treatment in April
Thousand Oaks-based Amgen said Aug. 22 that the U.S. Food and Drug Administration will likely make a decision by April 26, 2012 on the biotech firm’s application to expand the use of its Xgeva bone treatment drug to treat advanced prostate cancer. Amgen, the largest biotech company in the world, said in a statement that Read More →
10-K report: Vitesse looks for profitability
In the space of a decade, Vitesse Semiconductor Corp. fell from the throne of a blue-chip stock to a largely unprofitable player in the communications industry.
Interlink earnings down 47%
Sensor technology company Interlink Electronics earned $718,000 in the second quarter, down 46.9 percent from $1.4 million a year ago.
NiMin reports $3.8M profit
NiMin Energy Corp. earned $3.8 million, or 6 cents per share, in the second quarter of the year, swinging back to black after a $2.5 million loss in the same period a year ago.
K-Swiss shares stumble on $20M loss
K-Swiss reported a second-quarter loss of $20 million, or 56 cents per share, on Aug. 4, tripping up analysts who had predicted a 30-cent per share loss.
ValueClick to buy Dotomi for $295M
ValueClick said Aug. 2 that it will pay $295 million to acquire Chicago-based online advertising firm Dotomi, the same day the Westlake Village-based firm announced earnings that beat analyst expectations.
PCBC earns $21M in Q2
Pacific Capital Bancorp took another step toward getting out from under its regulatory consent order, reporting second-quarter net income of $21 million, or 64 cents per share, on July 27.
